Page 1 | Search Results | Blood | American Society of Hematology

1-8 of 8

Sort by

Sort Order Select

Journal Articles

The Bruton's Tyrosine Kinase (BTK) Inhibitor Ibrutinib (PCI-32765) Promotes High Response Rate, Durable Remissions, and Is Tolerable in Treatment Naïve (TN) and Relapsed or Refractory (RR) Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) Patients Including Patients with High-Risk (HR) Disease: New and Updated Results of 116 Patients in a Phase Ib/II Study

John C. Byrd, MD, Richard R. Furman, MD, Steven Coutre, MD, Ian W. Flinn, MD, PhD, Jan A. Burger, MD, PhD, Kristie A. Blum, MD, Jeff Sharman, MD, Barbara Grant, MD, Jeffrey A. Jones, MD, MPH, William G. Wierda, MD, Ph.D., Weiqiang Zhao, MD PhD, Nyla A. Heerema, PhD, Amy J. Johnson, PhD, Anh Tran, Fong Clow, ScD, Lori Kunkel, MD, Danelle F. James, M.D, Susan O'Brien, MD

Blood (2012) 120 (21): 189.

https://doi.org/10.1182/blood.V120.21.189.189

Published: 2012

Journal Articles

BCL6 Expression and Treatment Delay Correlate with Adverse Outcome in Newly Diagnosed Primary CNS Lymphoma: Final Report of CALGB 50202 (Alliance)

James L. Rubenstein, M.D., Ph.D., Eric D. Hsi, MD, Jeffrey L. Johnson, Sin-Ho Jung, Barbara Grant, MD, Bruce D. Cheson, MD, Lawrence D. Kaplan, MD

Blood (2012) 120 (21): 301.

https://doi.org/10.1182/blood.V120.21.301.301

Published: 2012

Journal Articles

A Phase II Multicenter Study of the Histone Deacetylase Inhibitor (HDACi) Abexinostat (PCI-24781) in Relapsed/Refractory Follicular Lymphoma (FL) and Mantle Cell Lymphoma (MCL)

Andrew M. Evens, DO, MSc, Julie M Vose, MD, MBA, Wael Harb, MD, Leo I. Gordon, MD, Robert Langdon, MD, Barbara Grant, MD, Julian Sprague, MD, PhD, Clara Plasencia, MS, Mint Sirisawad, MS, Jeanne Yue, MS, Ying Luan, PhD, Aaron Siek, BS, Lei Zhou, MD, Sriram Balasubramanian, PhD, Nancy L. Bartlett, MD

Blood (2012) 120 (21): 55.

https://doi.org/10.1182/blood.V120.21.55.55

Published: 2012

Journal Articles

The Bruton's Tyrosine Kinase (BTK) Inhibitor PCI-32765 Induces Durable Responses in Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): Follow-up of a Phase Ib/II Study

Susan O'Brien, MD, Jan A. Burger, MD, PhD, Kristie A. Blum, MD, Richard R. Furman, MD, Steven E. Coutre, MD, Jeff Sharman, MD, Ian W. Flinn, MD, PhD, Barbara Grant, MD, Nyla A. Heerema, PhD, Amy J. Johnson, PhD, Tasheda Navarro, Eric Holmgren, PhD, Eric Hedrick, MD, John C. Byrd, MD

Blood (2011) 118 (21): 983.

https://doi.org/10.1182/blood.V118.21.983.983

Published: 2011

Journal Articles

The Btk Inhibitor, PCI-32765, Induces Durable Responses with Minimal Toxicity In Patients with Relapsed/Refractory B-Cell Malignancies: Results From a Phase I Study

Nathan Fowler, MD, Jeff Porte Sharman, MD, Sonali M Smith, MD, Thomas Boyd, MD, Barbara Grant, MD, Kathryn S. Kolibaba, MD, Richard R. Furman, MD, Joseph Buggy, David Loury, PhD, Ahmed Hamdy, Ranjana Advani, MD

Blood (2010) 116 (21): 964.

https://doi.org/10.1182/blood.V116.21.964.964

Published: 2010

Journal Articles

Combination Biologic Therapy as Initial Treatment for Follicular Lymphoma: Initial Results From CALGB 50701 - a Phase II Trial of Extended Induction Epratuzumab (anti-CD22) and Rituximab (anti-CD20)

Barbara Grant, MD, John P. Leonard, MD, Jeffrey L Johnson, Lale Kostakoglu, Eric Hsi, MD, John C. Byrd, MD, Jeffrey A. Jones, MD, MPH, Sin-Ho Jung, Bruce D. Cheson, MD

Blood (2010) 116 (21): 427.

https://doi.org/10.1182/blood.V116.21.427.427

Published: 2010

Journal Articles

90 Y-Ibritumomab Tiuxetan Followed by Rituximab Is a Safe Treatment Option for Relapsed or Refractory Diffuse Large B-Cell Non-Hodgkin s Lymphoma

Katarina Luptakova, MD, Michelle Kim, Pamela Ely, MD, PhD, Barbara Grant, MD, John Anthony Parker, MD, PhD, Dimitrios Tzachanis, MD, PhD, Jacalyn Rosenblatt, MD, MSc, James Levine, MD, David Avigan, MD, Robin Joyce, MD

Blood (2010) 116 (21): 2866.

https://doi.org/10.1182/blood.V116.21.2866.2866

Published: 2010

Journal Articles

90 Y Ibritumomab Tiuxetan and Rituximab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Non-Hodgkin’s Lymphoma.

Michael S. Buff, MD, Anna Royer, BA, Pamela Ely, MD, PhD, Barbara Grant, MD, J. Anthony Parker, MD, PhD, Robin M. Joyce, MD

Blood (2006) 108 (11): 2752.

https://doi.org/10.1182/blood.V108.11.2752.2752

Published: 2006

NARROW

BCL6 Expression and Treatment Delay Correlate with Adverse Outcome in Newly Diagnosed Primary CNS Lymphoma: Final Report of CALGB 50202 (Alliance)

A Phase II Multicenter Study of the Histone Deacetylase Inhibitor (HDACi) Abexinostat (PCI-24781) in Relapsed/Refractory Follicular Lymphoma (FL) and Mantle Cell Lymphoma (MCL)

The Bruton's Tyrosine Kinase (BTK) Inhibitor PCI-32765 Induces Durable Responses in Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): Follow-up of a Phase Ib/II Study

The Btk Inhibitor, PCI-32765, Induces Durable Responses with Minimal Toxicity In Patients with Relapsed/Refractory B-Cell Malignancies: Results From a Phase I Study

Combination Biologic Therapy as Initial Treatment for Follicular Lymphoma: Initial Results From CALGB 50701 - a Phase II Trial of Extended Induction Epratuzumab (anti-CD22) and Rituximab (anti-CD20)

90 Y-Ibritumomab Tiuxetan Followed by Rituximab Is a Safe Treatment Option for Relapsed or Refractory Diffuse Large B-Cell Non-Hodgkin s Lymphoma

90 Y Ibritumomab Tiuxetan and Rituximab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Non-Hodgkin’s Lymphoma.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only